Royce & Associates LP Eagle Pharmaceuticals, Inc. Transaction History

Royce & Associates LP

  • $10.5 Billion
  • Q3 2024

A detailed history of Royce & Associates LP transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 13,821 shares of EGRX stock, worth $13,129. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,821
Previous 13,821 -0.0%
Holding current value
$13,129
Previous $77,000 33.77%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$4.26 - $6.51 $58,877 - $89,974
13,821 New
13,821 $72,000
Q3 2023

Nov 09, 2023
SELL
$15.21 - $22.88 $131,809 - $198,278
-8,666 Reduced 14.64%
50,548 $797,000
Q2 2023

Aug 07, 2023
BUY
$17.74 - $31.87 $205,464 - $369,118
11,582 Added 24.32%
59,214 $1.15 Million
Q1 2023

May 04, 2023
BUY
$25.06 - $34.09 $311,671 - $423,977
12,437 Added 35.34%
47,632 $1.35 Million
Q4 2022

May 23, 2023
SELL
$24.98 - $39.77 $310,676 - $494,619
-12,437 Reduced 26.11%
35,195 $1.03 Million
Q4 2022

Feb 13, 2023
BUY
$24.98 - $39.77 $282,773 - $450,196
11,320 Added 47.41%
35,195 $1.03 Million
Q3 2022

Nov 03, 2022
SELL
$26.42 - $47.12 $173,051 - $308,636
-6,550 Reduced 21.53%
23,875 $631,000
Q2 2022

Aug 04, 2022
SELL
$41.26 - $51.35 $255,688 - $318,215
-6,197 Reduced 16.92%
30,425 $1.35 Million
Q1 2022

May 05, 2022
BUY
$44.58 - $52.6 $801,459 - $945,642
17,978 Added 96.43%
36,622 $1.81 Million
Q4 2021

Feb 07, 2022
BUY
$45.82 - $56.9 $89,990 - $111,751
1,964 Added 11.77%
18,644 $949,000
Q3 2021

Nov 10, 2021
BUY
$43.79 - $55.78 $38,622 - $49,197
882 Added 5.58%
16,680 $930,000
Q2 2021

Aug 06, 2021
BUY
$36.86 - $44.5 $27,350 - $33,019
742 Added 4.93%
15,798 $676,000
Q1 2021

May 10, 2021
BUY
$40.32 - $50.97 $96,848 - $122,429
2,402 Added 18.98%
15,056 $628,000
Q4 2020

Feb 08, 2021
SELL
$41.72 - $51.34 $2,711 - $3,337
-65 Reduced 0.51%
12,654 $589,000
Q3 2020

Nov 12, 2020
SELL
$37.02 - $51.28 $927,202 - $1.28 Million
-25,046 Reduced 66.32%
12,719 $540,000
Q2 2020

Aug 07, 2020
SELL
$43.24 - $55.02 $600,257 - $763,787
-13,882 Reduced 26.88%
37,765 $1.81 Million
Q1 2020

May 12, 2020
BUY
$34.37 - $60.07 $57,088 - $99,776
1,661 Added 3.32%
51,647 $2.38 Million
Q4 2019

Feb 06, 2020
SELL
$54.32 - $64.31 $476,983 - $564,706
-8,781 Reduced 14.94%
49,986 $3 Million
Q3 2019

Nov 13, 2019
SELL
$53.25 - $59.98 $472,114 - $531,782
-8,866 Reduced 13.11%
58,767 $3.32 Million
Q2 2019

Aug 12, 2019
BUY
$46.61 - $58.45 $146,821 - $184,117
3,150 Added 4.89%
67,633 $3.77 Million
Q1 2019

May 09, 2019
BUY
$38.66 - $51.82 $1.06 Million - $1.42 Million
27,344 Added 73.63%
64,483 $3.26 Million
Q4 2018

Feb 11, 2019
SELL
$36.72 - $67.73 $142,987 - $263,740
-3,894 Reduced 9.49%
37,139 $1.5 Million
Q3 2018

Nov 13, 2018
BUY
$66.65 - $83.86 $50,520 - $63,565
758 Added 1.88%
41,033 $2.85 Million
Q2 2018

Aug 09, 2018
SELL
$51.25 - $76.62 $1.53 Million - $2.28 Million
-29,768 Reduced 42.5%
40,275 $3.05 Million
Q1 2018

May 14, 2018
SELL
$52.16 - $66.86 $1.11 Million - $1.42 Million
-21,291 Reduced 23.31%
70,043 $3.69 Million
Q4 2017

Feb 09, 2018
BUY
$49.6 - $60.87 $1.16 Million - $1.43 Million
23,418 Added 34.48%
91,334 $4.88 Million
Q3 2017

Nov 13, 2017
BUY
$46.62 - $60.36 $3.17 Million - $4.1 Million
67,916
67,916 $4.05 Million

Others Institutions Holding EGRX

# of Institutions
70
Shares Held
8.59M
Call Options Held
1M
Put Options Held
100
View Full List

About EAGLE PHARMACEUTICALS, INC.

EGRX Quotes by TradingView
  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $12.4M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email